ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report published on Monday,Benzinga reports. The brokerage currently has a $30.00 target price on the stock.

A number of other equities analysts have also recently issued reports on IBRX. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of ImmunityBio in a report on Thursday, March 13th. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $3.05 on Monday. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -3.32 and a beta of 0.82. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The company’s 50-day simple moving average is $3.12 and its 200-day simple moving average is $3.59.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. As a group, research analysts forecast that ImmunityBio will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of ImmunityBio during the fourth quarter worth approximately $37,000. Waverly Advisors LLC acquired a new position in ImmunityBio during the 4th quarter worth $38,000. Woodline Partners LP grew its stake in shares of ImmunityBio by 682.7% in the fourth quarter. Woodline Partners LP now owns 3,442,440 shares of the company’s stock worth $8,813,000 after purchasing an additional 3,002,622 shares in the last quarter. Wexford Capital LP bought a new stake in shares of ImmunityBio during the fourth quarter valued at about $85,000. Finally, Two Sigma Investments LP acquired a new stake in ImmunityBio in the fourth quarter worth about $72,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.